



**HEMATOPATHOLOGY
DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE
RECOMMENDED THERAPEUTIC RANGES IN THROMBOSIS & HEMOSTASIS**

For further details regarding timing requirements, see the Anticoagulant Resources page in the IU Health Team Member Portal. Access at <https://team.myiuhhealth.org/patient-care/pharmacy/pharmacy-resources-education/clinical-pharmacy-topics/anticoagulation-regulation>.

DRUG	LAB MONITORING
Argatroban¹ (HIT) *	Target aPTT 45 – 90 seconds . Repeat 4 hours from last aPTT
Bivalirudin² (HIT) *	Target aPTT 45 – 60 seconds . Repeat 4 hours from last aPTT.
UNFH	Target aPTT range 52-84 seconds Target Anti-Xa Unfractionated 0.3-0.7 IU/mL
LMWH³	Target Anti-Xa Enoxaparin 0.5 – 1.0 IU/mL
Coumadin	Target INR 2.0-3.0 Target INR Prosthetic Heart Valves 2.0-3.5
Fondaparinux⁴	Target Anti-Xa Fondaparinux Mean peak steady-state range 1.20-1.26mg/L Mean minimum steady-state range 0.46-0.62mg/L (package insert) *** In patients with symptomatic deep vein thrombosis and pulmonary embolism undergoing treatment with fondaparinux sodium injection 5mg (body weight <50kg), 7.5 mg (body weight 50-100kg), and 10 mg (body weight >100kg) once daily, the body-weight-adjusted doses provide similar mean steady-state peaks and minimum plasma concentrations across all body weight categories.
Oral Anticoagulant with concurrent direct thrombin inhibitor or LA.	Target Chromogenic X Assay 51-15%, correlates to INR of 2.0-3.5

* **DOSES SHOULD BE ADJUSTED FOR HEPATIC IMPAIRMENT**

¹“Argatroban Injection, Prescribing Information”, accessed 3/2/18, <https://hemonc.org/docs/packageinsert/argatroban.pdf>
<https://pulse.iuhealth.org/portal/intranet/home/contentfull?url=/depts/pharmacy/PharmacyProtocols/DirectThrombinInhibitors.pdf>

²“Angiomax® (bivalirudin) for injection, Prescribing Information”, accessed 3/2/18, <https://hemonc.org/docs/packageinsert/bivalirudin.pdf>
<https://pulse.iuhealth.org/portal/intranet/home/contentfull?url=/depts/pharmacy/PharmacyProtocols/DirectThrombinInhibitors.pdf>

³“The Clinical Use and Laboratory Monitoring of Low-Molecular-Weight Heparin, Danaparoid, Hirudin, and Related Compounds, and Argatroban”. Michael Laosata, MD; David Green, MD, PhD; Elizabeth M. Van Cott, MD; Trevor W Barrowcliffe, PhD; Scott H. Goodnight, MD; Randolph C Sosolik, MD. Archives Pathology Laboratory Medicine, Vol 122, September 1998, pages 799-807.

⁴“Arixtra[®] Prescribing Information”, accessed 3/2/18, https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021345s010lbl.pdf